...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Report Of Exempt Distribution.

On the plus side: whoever threw that money in doesn't think Hepa will be an issue.

Share
New Message
Please login to post a reply